InsiderSignal.AI

InsiderSignal.ai

IONS - Ionis Pharmaceuticals Inc

Insider Sale by Klein Joseph III (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Klein Joseph III, serving as Dir at Ionis Pharmaceuticals Inc (IONS), sold 22,321 shares at $75.55 per share, for a total transaction value of $1,686,302.00. Following this transaction, Klein Joseph III now holds 11,114 shares of IONS.

This sale represents a 67.00% decrease in Klein Joseph III's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, April 1, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 2, 2026, 1 day after the trade was made.

Ionis Pharmaceuticals Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Klein Joseph III

Dir

Joseph "Skip" Klein III is an independent director at Ionis Pharmaceuticals Inc (IONS) since December 2005, currently serving as Audit Committee Chair and Finance Committee member, where he is designated as the Audit Committee's financial expert due to his Chartered Financial Analyst (CFA) credential and extensive experience[[1]](https://fintool.com/app/research/companies/IONS/people/joseph-klein-iii)[[4]](https://ionis.com/about-us/our-leadership)[[5]](https://simplywall.st/stocks/gb/pharmaceuticals-biotech/lse-0jdi/ionis-pharmaceuticals-shares/management). Klein, aged 63 as of March 1, 2025, is the Managing Director of Gauss Capital Advisors, a biopharma-focused advisory firm he founded in 1998[[1]](https://fintool.com/app/research/companies/IONS/people/joseph-klein-iii)[[4]](https://ionis.com/about-us/our-leadership). His career highlights include serving as founding portfolio manager of the T. Rowe Price Health Sciences Fund (1989–1998), VP of Strategy at Medical Manager Corporation (pre-merger with WebMD, 1999–2000), and venture partner roles at MPM Capital (2001–2002) and Red Abbey Venture Partners (2003–2008)[[1]](https://fintool.com/app/research/companies/IONS/people/joseph-klein-iii). He has held prior directorships at public companies including Akcea Therapeutics (until its 2020 merger with Ionis), BioMarin, NPS, OSI, PDL BioPharma, and Savient, and currently serves on the board of The Prospector Funds[[1]](https://fintool.com/app/research/companies/IONS/people/joseph-klein-iii). Recently, as a corporate insider, Klein executed Rule 10b5-1 trades, selling shares on September 3, 2025 ($1.68M) and November 25, 2025 ($960K) after exercising stock options, retaining direct ownership of 16,346 shares[[2]](https://www.investing.com/news/insider-trading-news/ionis-pharma-director-klein-sells-960k-in-ions-stock-93CH-4382494)[[3]](https://www.investing.com/news/insider-trading-news/ionis-pharma-director-klein-sells-168-million-in-shares-93CH-4225885).

View full insider profile →

Trade Price

$75.55

Quantity

22,321

Total Value

$1,686,302.00

Shares Owned

11,114

Trade Date

Wednesday, April 1, 2026

4 days ago

SEC Filing Date

Thursday, April 2, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Ionis Pharmaceuticals Inc

Company Overview

No company information available
View news mentioning IONS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5328369

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime